Trials / Active Not Recruiting
Active Not RecruitingNCT06846515
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AR882 50 mg | Solid Oral Capsule |
| DRUG | AR882 75 mg | Solid Oral Capsule |
| DRUG | Placebo | Matching Solid Oral Capsule Placebo |
Timeline
- Start date
- 2025-03-11
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2025-02-26
- Last updated
- 2025-09-17
Locations
89 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06846515. Inclusion in this directory is not an endorsement.